☆ 4.3 Meeting Abstract

Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody, for X-Linked Hypophosphatemia (XLH): Sustained Improvement in Two Phase 2 Trials in Affected Children 1-12 Years Old

HORMONE RESEARCH IN PAEDIATRICS (2018)

Add to Collection

Journal

HORMONE RESEARCH IN PAEDIATRICS
Volume 90, Issue -, Pages 30-30

Publisher

KARGER

Keywords

-

Categories

Endocrinology & Metabolism Pediatrics

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.